VIVORYON overview

Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease A meta-analysis of VIVIAD and VIVA-MIND 1 data confirmed that treatment with varoglutamstat at 600mg twice daily significantly improved eGFR 2 kidney function in the overall study population The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes 3 compared to those without diabetes Vivoryon further strengthened its patent portfolio for...

Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR 1 ) versus placebo in two independent randomized double-blind placebo-controlled studies VIVA-MIND topline analysis of kidney function data reported yesterday provides a second Phase 2 long-term dataset demonstrating varoglutamstat’s...

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function VIVA-MIND Phase 2 data confirm results of varoglutamstat’s benefit on eGFR in VIVIAD; Company now has two independent double-blind placebo-controlled Phase 2 studies demonstrating a clinically meaningful treatment effect on kidney function Topline analysis of kidney function data in VIVA-MIND shows a statistically significant and clinically...

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Halle (Saale) / Munich, Germany, December 04, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its third quarter financial results for the period...

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Selected for late-breaking oral presentation at ASN kidney week, the world’s premier nephrology meeting Results presented show a statistically significant and clinically meaningful improvement of the prospectively defined kidney function parameter eGFR 1 by 3.4mL/min/year (p<0.0001) in the varoglutamstat arm compared to placebo Results in the subgroup of patients with...

Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat...

Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual Kidney Disease Key Opinion Leader (KOL) Event held September 30, 2024. The event focused on the standard of care and existing medical need, market...

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Primary focus is developing varoglutamstat, a Phase 2 investigational medicine with potential to improve kidney function in patients with kidney disease Statistically significant benefit of varoglutamstat on prospectively defined key kidney function endpoint (eGFR 1 ) and significant reduction of pro-inflammatory cytokine pE-CCL2...